Joannes H J M Van Krieken

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/738735/publications.pdf

Version: 2024-02-01

289 papers

36,037 citations

72 h-index 184

g-index

290 all docs

290 docs citations

290 times ranked

34872 citing authors

#	Article	IF	CITATIONS
1	Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database. Future Oncology, 2021, 17, 1483-1494.	2.4	7
2	The tumour–stroma ratio in colon cancer: the biological role and its prognostic impact. Histopathology, 2018, 73, 197-206.	2.9	97
3	External Quality Assessment Identifies Training Needs to Determine the Neoplastic Cell Content for Biomarker Testing. Journal of Molecular Diagnostics, 2018, 20, 455-464.	2.8	16
4	RAS testing for colorectal cancer patients is reliable in European laboratories that pass external quality assessment. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 717-725.	2.8	7
5	Detection of EGFR Variants in Plasma. Journal of Molecular Diagnostics, 2018, 20, 483-494.	2.8	37
6	Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy. Leukemia, 2018, 32, 353-363.	7.2	36
7	Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. Neoplasia, 2018, 20, 574-593.	5. 3	64
8	Recurrent mutations in genes involved in nuclear factorâ€PB signalling in nodal marginal zone lymphoma—diagnostic and therapeutic implications. Histopathology, 2017, 70, 174-184.	2.9	21
9	Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations. British Journal of Cancer, 2017, 117, 1685-1688.	6.4	13
10	Novel developments in the pathogenesis and diagnosis of extranodal marginal zone lymphoma. Journal of Hematopathology, 2017, 10, 91-107.	0.4	45
11	New developments in the pathology of malignant lymphoma: a review of the literature published from May to August 2017. Journal of Hematopathology, 2017, 10, 65-73.	0.4	8
12	Unraveling genetic predisposition to familial or early onset gastric cancer using germline whole-exome sequencing. European Journal of Human Genetics, 2017, 25, 1246-1252.	2.8	34
13	Quality in pathology. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 311-312.	2.8	O
14	Will the liquid biopsy replace traditional hematopathology?. Journal of Hematopathology, 2017, 10, 1-1.	0.4	0
15	<i>RAS</i> mutation prevalence among patients with metastatic colorectal cancer: a meta-analysis of real-world data. Biomarkers in Medicine, 2017, 11, 751-760.	1.4	33
16	Pathways towards indolent B-cell lymphoma â€" Etiology and therapeutic strategies. Blood Reviews, 2017, 31, 426-435.	5.7	7
17	Multispectral imaging for highly accurate analysis of tumourâ€infiltrating lymphocytes in primary melanoma. Histopathology, 2017, 70, 643-649.	2.9	14
18	Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma. Leukemia, 2017, 31, 625-636.	7.2	47

#	Article	IF	Citations
19	Targeting the environment. Journal of Hematopathology, 2017, 10, 47-47.	0.4	O
20	New developments in the pathology of malignant lymphoma. A review of the literature published from September–August 2017. Journal of Hematopathology, 2017, 10, 117-127.	0.4	3
21	Editorial: when to be an author?. Journal of Hematopathology, 2017, 10, 89-90.	0.4	1
22	High mRNA expression of splice variant SYK short correlates with hepatic disease progression in chemonaive lymph node negative colon cancer patients. PLoS ONE, 2017, 12, e0185607.	2.5	14
23	Direct inhibition of STAT signaling by platinum drugs contributes to their anti-cancer activity. Oncotarget, 2017, 8, 54434-54443.	1.8	13
24	Prognostic impact of concurrent <i>MYC</i> and <i>BCL6</i> rearrangements and expression in <i>de novo</i> diffuse large B-cell lymphoma. Oncotarget, 2016, 7, 2401-2416.	1.8	93
25	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology, 2016, 27, 1386-1422.	1.2	2,545
26	Are we making progress?. Journal of Hematopathology, 2016, 9, 51-51.	0.4	1
27	Clinical and Biologic Significance of <i>MYC</i> Genetic Mutations in <i>De Novo</i> Diffuse Large B-cell Lymphoma. Clinical Cancer Research, 2016, 22, 3593-3605.	7.0	48
28	The Role of Dectin-2 for Host Defense Against Disseminated Candidiasis. Journal of Interferon and Cytokine Research, 2016, 36, 267-276.	1.2	45
29	T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines. Cancer Research, 2016, 76, 3496-3506.	0.9	33
30	New developments in the pathology of malignant lymphoma. A review of the literature published from January–April 2016. Journal of Hematopathology, 2016, 9, 73-83.	0.4	3
31	New developments in the pathology of malignant lymphoma: a review of the literature published from June–August 2016. Journal of Hematopathology, 2016, 9, 129-134.	0.4	2
32	Open access and data. Journal of Hematopathology, 2016, 9, 105-105.	0.4	0
33	We need to be (much) better. Journal of Hematopathology, 2016, 9, 1-1.	0.4	O
34	How we do: optimizing bone marrow biopsy logistics for sign-out within 2Âdays. Journal of Hematopathology, 2016, 9, 67-71.	0.4	2
35	New developments in the pathology of malignant lymphoma. A review of the literature published from September 2015–December 2015. Journal of Hematopathology, 2016, 9, 19-27.	0.4	3
36	Clinical features of patients with nodal marginal zone lymphoma compared to follicular lymphoma: similar presentation, but differences in prognostic factors and rate of transformation. Leukemia and Lymphoma, 2016, 57, 1649-1656.	1.3	13

#	Article	IF	Citations
37	RAS testing in metastatic colorectal cancer: advances in Europe. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 383-396.	2.8	27
38	A 20-year population-based study on the epidemiology, clinical features, treatment, and outcome of nodular lymphocyte predominant Hodgkin lymphoma. Annals of Hematology, 2016, 95, 417-423.	1.8	18
39	A subset of low-grade B cell lymphomas with a follicular growth pattern but without a BCL2 translocation shows features suggestive of nodal marginal zone lymphoma. Journal of Hematopathology, 2016, 9, 3-8.	0.4	7
40	Tetraspanin CD37 protects against the development of B cell lymphoma. Journal of Clinical Investigation, 2016, 126, 653-666.	8.2	47
41	p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function. Aging, 2016, 8, 345-365.	3.1	19
42	RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphoma. Aging, 2016, 8, 3321-3340.	3.1	29
43	Identification of IG-clonality status as a pre-treatment predictor for mortality in patients with immunodeficiency-associated Epstein-Barr virus-related lymphoproliferative disorders. Haematologica, 2015, 100, e152-e154.	3.5	2
44	We are not our genes. Journal of Hematopathology, 2015, 8, 201-202.	0.4	0
45	Reduced Circumferential Resection Margin Involvement in Rectal Cancer Surgery: Results of the Dutch Surgical Colorectal Audit. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1111-1119.	4.9	19
46	Panitumumab Use in Metastatic Colorectal Cancer and Patterns of KRAS Testing: Results from a Europe-Wide Physician Survey and Medical Records Review. PLoS ONE, 2015, 10, e0140717.	2.5	9
47	Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma. Oncotarget, 2015, 6, 5597-5614.	1.8	61
48	New developments in the pathology of malignant lymphoma: a review of the literature published from May 2015–September 2015. Journal of Hematopathology, 2015, 8, 225-234.	0.4	2
49	Immunohistochemical differentiation between follicular lymphoma and nodal marginal zone lymphoma - combined performance of multiple markers. Haematologica, 2015, 100, e358-e360.	3.5	20
50	Gastric cancer in three relatives of a patient with a biallelic IL12RB1 mutation. Familial Cancer, 2015, 14, 89-94.	1.9	14
51	Epstein–Barr Virus in Inflammatory Bowel Disease: The Spectrum of Intestinal Lymphoproliferative Disorders. Journal of Crohn's and Colitis, 2015, 9, 398-403.	1.3	70
52	Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline <i>CDH1</i> mutation carriers. Journal of Medical Genetics, 2015, 52, 361-374.	3.2	479
53	Trends in quality of non-Hodgkin's lymphoma care: is it getting better?. Annals of Hematology, 2015, 94, 1195-1203.	1.8	3
54	A germline homozygous mutation in the base-excision repair gene NTHL1 causes adenomatous polyposis and colorectal cancer. Nature Genetics, 2015, 47, 668-671.	21.4	311

#	Article	IF	Citations
55	New developments in the pathology of malignant lymphoma: a review of the literature published from October 2014–December 2014. Journal of Hematopathology, 2015, 8, 21-29.	0.4	1
56	New developments in the pathology of malignant lymphoma: a review of literature published from January 2015 to April 2015. Journal of Hematopathology, 2015, 8, 71-79.	0.4	2
57	Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Modern Pathology, 2015, 28, 1555-1573.	5 . 5	48
58	Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. Modern Pathology, 2015, 28, 1297-1314.	5 . 5	21
59	The homogeneous mutation status of a 22 gene panel justifies the use of serial sections of colorectal cancer tissue for external quality assessment. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 467, 273-278.	2.8	11
60	Paediatric hematopathology: something real special. Journal of Hematopathology, 2015, 8, 99-99.	0.4	0
61	Immunoglobulin rearrangement analysis from multiple lesions in the same patient using nextâ€generation sequencing. Histopathology, 2015, 67, 843-858.	2.9	5
62	Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. Modern Pathology, 2015, 28, 1202-1213.	5 . 5	17
63	External Quality Assessment Unravels Interlaboratory Differences in Quality of RAS Testing for Antiâ€EGFR Therapy in Colorectal Cancer. Oncologist, 2015, 20, 257-262.	3.7	39
64	Clinical and biological significance of <i>de novo</i> CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget, 2015, 6, 5615-5633.	1.8	72
65	RAS testing in metastatic colorectal cancer: excellent reproducibility amongst 17 Dutch pathology centers. Oncotarget, 2015, 6, 15681-15689.	1.8	12
66	Prognostic impact of c-Rel nuclear expression and <i>REL</i> amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. Oncotarget, 2015, 6, 23157-23180.	1.8	35
67	Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma-is it necessary?. Oncotarget, 2015, 6, 13933-13945.	1.8	33
68	Evaluation of a panel of expert pathologists: review of the diagnosis and histological classification of Hodgkin and non-Hodgkin lymphomas in a population-based cancer registry. Leukemia and Lymphoma, 2014, 55, 1018-1022.	1.3	11
69	Phenotypic and Genotypic Profiling of MDM2, Respective to the TP53 Genetic Status, in Diffuse Large B-cell Lymphoma Patients Treated With Rituximab-CHOP Immunochemotherapy: A Report from the International DLBCL Rituximab-CHOP Consortium Program. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, S146-S147.	0.4	O
70	Role of Dectin-2 for Host Defense against Systemic Infection with Candida glabrata. Infection and Immunity, 2014, 82, 1064-1073.	2.2	100
71	Sequential immunohistochemistry: a promising new tool for the pathology laboratory. Histopathology, 2014, 65, 651-657.	2.9	44
72	Prevalence and Clinical Implications of Epstein–Barr Virus Infection in <i>De Novo</i> Diffuse Large B-Cell Lymphoma in Western Countries. Clinical Cancer Research, 2014, 20, 2338-2349.	7.0	117

#	Article	IF	CITATIONS
73	HNF4A immunohistochemistry facilitates distinction between primary and metastatic breast and gastric carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 464, 673-679.	2.8	26
74	Limited diagnostic value of microsatellite instability associated pathology features in colorectal cancer. Familial Cancer, 2014, 13, 351-359.	1.9	3
75	Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Modern Pathology, 2014, 27, 958-971.	5.5	112
76	Clinical Implications of Phosphorylated STAT3 Expression in <i>De Novo</i> Diffuse Large B-cell Lymphoma. Clinical Cancer Research, 2014, 20, 5113-5123.	7.0	60
77	Prevalence and clinical implications of cyclin D1 expression in diffuse large Bâ€cell lymphoma (DLBCL) treated with immunochemotherapy: A report from the International DLBCL Rituximabâ€CHOP Consortium Program. Cancer, 2014, 120, 1818-1829.	4.1	32
78	Higher Quality of Molecular Testing, an Unfulfilled Priority. Journal of Molecular Diagnostics, 2014, 16, 371-377.	2.8	22
79	The ileo neo rectal anastomosis: long-term results of surgical innovation in patients after ulcerative colitis and familial adenomatous polyposis. International Journal of Colorectal Disease, 2013, 28, 111-118.	2.2	5
80	Trends in incidence, therapy and outcome of localized nodal and extranodal marginal zone lymphomas: declining incidence and inferior outcome for gastrointestinal sites. Leukemia and Lymphoma, 2013, 54, 1891-1897.	1.3	17
81	Guideline on the requirements of external quality assessment programs in molecular pathology. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 462, 27-37.	2.8	70
82	KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 462, 39-46.	2.8	26
83	MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 121, 4021-4031.	1.4	596
84	CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood, 2013, 121, 2715-2724.	1.4	206
85	The evaluation of colon biopsies using virtual microscopy is reliable. Histopathology, 2013, 63, 114-121.	2.9	23
86	Diagnosing and classifying malignant lymphomas is improved by referring cases to a panel of expert pathologists. Journal of Hematopathology, 2013, 6, 179-185.	0.4	1
87	Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica, 2013, 98, 255-263.	3.5	142
88	Recognizing nodal marginal zone lymphoma: recent advances and pitfalls. A systematic review. Haematologica, 2013, 98, 1003-1013.	3.5	85
89	T(14;18)(q32;q21) involving MALT1 and IGH genes occurs in extranodal diffuse large B-cell lymphomas of the breast and testis. Modern Pathology, 2013, 26, 421-427.	5.5	20
90	European Consensus Conference for external quality assessment in molecular pathology. Annals of Oncology, 2013, 24, 1958-1963.	1.2	39

#	Article	IF	Citations
91	Undertreatment of patients with localized extranodal compared with nodal diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2013, 54, 1698-1705.	1.3	7
92	Single nucleotide variation in the TP53 3′ untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 121, 4529-4540.	1.4	41
93	MYC Mutation Profiling In 708 De Novo Diffuse Large B-Cell Lymphoma Demonstrates That Genetic Abnormalities In The Coding Sequence and Untranslated Regions Have Different Prognostic and Clinical Significance: A Report From The International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013. 122. 363-363.	1.4	0
94	Centralised multidisciplinary re-evaluation of diagnostic procedures in patients with newly diagnosed Hodgkin lymphoma. Annals of Oncology, 2012, 23, 2676-2681.	1.2	10
95	Higher cytoplasmic and nuclear poly(ADP-ribose) polymerase expression in familial than in sporadic breast cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 461, 425-431.	2.8	4
96	Application of Microfluidic Technology to the BIOMED-2 Protocol for Detection of B-Cell Clonality. Journal of Molecular Diagnostics, 2012, 14, 30-37.	2.8	21
97	Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia, 2012, 26, 2103-2113.	7.2	301
98	Familial gastric cancer: guidelines for diagnosis, treatment and periodic surveillance. Familial Cancer, 2012, 11, 363-369.	1.9	71
99	Clinical and pathological features of testicular diffuse large B-cell lymphoma: a heterogeneous disease. Leukemia and Lymphoma, 2012, 53, 242-246.	1.3	14
100	Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer. New England Journal of Medicine, 2012, 366, 2074-2084.	27.0	4,296
101	Molecular pathogenesis and histologic and clinical features of extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue type. Leukemia and Lymphoma, 2012, 53, 1032-1045.	1.3	18
102	Implementation of Formalin-Fixed, Paraffin-Embedded Cell Line Pellets as High-Quality Process Controls in Quality Assessment Programs for KRAS Mutation Analysis. Journal of Molecular Diagnostics, 2012, 14, 187-191.	2.8	13
103	<i>CDH1</i> â€related hereditary diffuse gastric cancer syndrome: Clinical variations and implications for counseling. International Journal of Cancer, 2012, 131, 367-376.	5.1	110
104	Psychological distress in newly diagnosed colorectal cancer patients following microsatellite instability testing for Lynch syndrome on the pathologist's initiative. Familial Cancer, 2012, 11, 259-267.	1.9	16
105	The times have changed: molecular pathology is here to stay. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 460, 129-130.	2.8	3
106	Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncology, The, 2011, 12, 49-55.	10.7	232
107	Preparing pathology for personalized medicine: possibilities for improvement of the pre-analytical phase. Histopathology, 2011, 59, 1-7.	2.9	44
108	Inter-observer variation in the histological diagnosis of polyps in colorectal cancer screening. Histopathology, 2011, 58, 974-981.	2.9	46

#	Article	IF	Citations
109	Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation. European Journal of Human Genetics, 2011, 19, 870-874.	2.8	141
110	KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. British Journal of Cancer, 2011, 104, 1020-1026.	6.4	262
111	Variation in Lymph Node Evaluation in Rectal Cancer: A Dutch Nationwide Population-Based Study. Annals of Surgical Oncology, 2011, 18, 386-395.	1.5	21
112	Mutation analysis of KRAS prior to targeted therapy in colorectal cancer: development and evaluation of quality by a European external quality assessment scheme. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 459, 155-160.	2.8	18
113	Recurrence and variability of germline <i>EPCAM</i> deletions in Lynch syndrome. Human Mutation, 2011, 32, 407-414.	2.5	137
114	Identification of candidate predisposing copy number variants in familial and earlyâ€onset colorectal cancer patients. International Journal of Cancer, 2011, 129, 1635-1642.	5.1	66
115	Cellular angiofibroma: analysis of 25 cases emphasizing its relationship to spindle cell lipoma and mammary-type myofibroblastoma. Modern Pathology, 2011, 24, 82-89.	5 . 5	159
116	External Quality Assessment for <i>KRAS</i> Testing Is Needed: Setup of a European Program and Report of the First Joined Regional Quality Assessment Rounds. Oncologist, 2011, 16, 467-478.	3.7	83
117	Large variation between hospitals and pathology laboratories in lymph node evaluation in colon cancer and its impact on survival, a nationwide population-based study in The Netherlands. Annals of Oncology, 2011, 22, 110-117.	1.2	39
118	Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. Journal of Clinical Investigation, 2011, 121, 3100-3108.	8.2	271
119	The t(14;18)(q32;q21) Characterizes a Subset of Patients with Diffuse Large-B Cell Lymphoma of Germinal Center Origin with Poor Outcome: Report From the International DLBCL Rituximab-CHOP Consortium Program Study. Blood, 2011, 118, 949-949.	1.4	3
120	High sensitivity of both sequencing and realâ€time PCR analysis of <i>KRAS</i> mutations in colorectal cancer tissue. Journal of Cellular and Molecular Medicine, 2010, 14, 2122-2131.	3.6	73
121	Overlap, Common Features, and Essential Differences in Pediatric Granulomatous Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition, 2010, 51, 690-697.	1.8	56
122	Electronic reminders for pathologists promote recognition of patients at risk for Lynch syndrome: cluster-randomised controlled trial. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2010, 456, 653-659.	2.8	17
123	New developments in the pathology of malignant lymphoma: a review of the literature published from October 2009 to January 2010. Journal of Hematopathology, 2010, 3, 47-58.	0.4	1
124	Hematopathology in the new decade: what to expect. Journal of Hematopathology, 2010, 3, 1-1.	0.4	0
125	Myxoid epithelioid sarcoma: a diagnostic challenge. A report on six cases. Histopathology, 2010, 57, 753-759.	2.9	25
126	Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases. British Journal of Cancer, 2010, 103, 159-164.	6.4	131

#	Article	IF	CITATIONS
127	Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. Journal of Medical Genetics, 2010, 47, 436-444.	3.2	495
128	Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. Journal of Medical Genetics, 2010, 47, 464-470.	3.2	165
129	Identification of a Quantitative <i>MINT</i> Locus Methylation Profile Predicting Local Regional Recurrence of Rectal Cancer. Clinical Cancer Research, 2010, 16, 2811-2818.	7.0	22
130	Molecular Pathology in Contemporary Diagnostic Pathology Laboratory. American Journal of Surgical Pathology, 2010, 34, e14.	3.7	2
131	DNA copy number profiles of primary tumors as predictors of response to chemotherapy in advanced colorectal cancer. Annals of Oncology, 2009, 20, 1048-1056.	1.2	41
132	In situ Expression of Tumor Antigens by Messenger RNA–Electroporated Dendritic Cells in Lymph Nodes of Melanoma Patients. Cancer Research, 2009, 69, 2927-2934.	0.9	56
133	High-resolution genomic profiling of pediatric lymphoblastic lymphomas reveals subtle differences with pediatric acute lymphoblastic leukemias in the B-lineage. Cancer Genetics and Cytogenetics, 2009, 191, 27-33.	1.0	30
134	Immunohistochemistry is not an accurate first step towards the molecular diagnosis of MUTYH-associated polyposis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2009, 454, 25-29.	2.8	8
135	PCR clonality detection in Hodgkin lymphoma. Journal of Hematopathology, 2009, 2, 34-41.	0.4	27
136	The second year of the Journal of Hematopathology has started. Journal of Hematopathology, 2009, 2, 1-1.	0.4	0
137	Ki-67 as a prognostic marker in mantle cell lymphomaâ€"consensus guidelines of the pathology panel of the European MCL Network. Journal of Hematopathology, 2009, 2, 103-111.	0.4	149
138	New developments in the pathology of malignant lymphoma: a review of the literature published from January to August 2009. Journal of Hematopathology, 2009, 2, 171-183.	0.4	1
139	Journal of Hematopathology listed in PubMed!. Journal of Hematopathology, 2009, 2, 133.	0.4	1
140	Hematopathology: a decade into the new millennium. Journal of Hematopathology, 2009, 2, 185-185.	0.4	0
141	In Lynch syndrome adenomas, loss of mismatch repair proteins is related to an enhanced lymphocytic response. Histopathology, 2009, 55, 414-422.	2.9	26
142	Compound heterozygosity for two MSH2 mutations suggests mild consequences of the initiation codon variant c.1A>G of MSH2. European Journal of Human Genetics, 2009, 17, 159-164.	2.8	21
143	Hypermutation in mantle cell lymphoma does not indicate a clinical or biological subentity. Modern Pathology, 2009, 22, 416-425.	5.5	27
144	Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the $3\hat{a} \in \mathbb{Z}^2$ exons of TACSTD1. Nature Genetics, 2009, 41, 112-117.	21.4	679

#	Article	IF	CITATIONS
145	Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. British Journal of Cancer, 2009, 100, 266-273.	6.4	392
146	Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer. New England Journal of Medicine, 2009, 360, 563-572.	27.0	1,243
147	Lymph Node Retrieval in Rectal Cancer is Dependent on Many Factors—the Role of the Tumor, the Patient, the Surgeon, the Radiotherapist, and the Pathologist. American Journal of Surgical Pathology, 2009, 33, 1547-1553.	3.7	113
148	Genetic Association Analysis of the Functional c.714T>G Polymorphism and Mucosal Expression of Dectin-1 in Inflammatory Bowel Disease. PLoS ONE, 2009, 4, e7818.	2.5	38
149	Glycogenic hepatopathy: a rare cause of elevated serum transaminases in diabetes mellitus. Netherlands Journal of Medicine, 2009, 67, 394-6.	0.5	38
150	Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation. Investigational New Drugs, 2008, 26, 393-397.	2.6	56
151	Clinical impact of HLA class I expression in rectal cancer. Cancer Immunology, Immunotherapy, 2008, 57, 601-609.	4.2	46
152	The Journal of Hematopathology: a new adventure!?. Journal of Hematopathology, 2008, 1, 1-1.	0.4	1
153	New developments in the pathology of malignant lymphoma: a review of the literature published from May to July 2008. Journal of Hematopathology, 2008, 1, 145-60.	0.4	5
154	Pitfalls in TCR gene clonality testing: teaching cases. Journal of Hematopathology, 2008, 1, 97-109.	0.4	76
155	Translocation detection in lymphoma diagnosis by split-signal FISH: a standardised approach. Journal of Hematopathology, 2008, 1, 119-126.	0.4	28
156	Welcome to the first printed issue of the Journal of Hematopathology. Journal of Hematopathology, 2008, 1, 75-75.	0.4	0
157	Most Patients with Colorectal Tumors at Young Age Do Not Visit a Cancer Genetics Clinic. Diseases of the Colon and Rectum, 2008, 51, 1249-1254.	1.3	32
158	Cysts of PRKCSH mutated polycystic liver disease patients lack hepatocystin but express Sec63p. Histochemistry and Cell Biology, 2008, 129, 301-310.	1.7	28
159	KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2008, 453, 417-431.	2.8	269
160	Is early-onset microsatellite and chromosomally stable colorectal cancer a hallmark of a genetic susceptibility syndrome?. International Journal of Cancer, 2008, 122, 796-801.	5.1	11
161	Intratumoral rhILâ€12 administration in head and neck squamous cell carcinoma patients induces B cell activation. International Journal of Cancer, 2008, 123, 2354-2361.	5.1	76
162	Disrupted cell adhesion but not proliferation mediates cyst formation in polycystic liver disease. Modern Pathology, 2008, 21, 1293-1302.	5.5	31

#	Article	IF	CITATIONS
163	Expression of P2X5 in lymphoid malignancies results in LRH-1-specific cytotoxic T-cell-mediated lysis. British Journal of Haematology, 2008, 141, 799-807.	2.5	33
164	Integrated genomic and expression profiling in mantle cell lymphoma: identification of geneâ€dosage regulated candidate genes. British Journal of Haematology, 2008, 143, 210-221.	2.5	27
165	Preoperative radiochemotherapy is successful also in patients with locally advanced rectal cancer who have intrinsically high apoptotic tumours. Annals of Oncology, 2008, 19, 2026-2032.	1.2	16
166	Epithelial Human Leukocyte Antigen-DR Expression Predicts Reduced Recurrence Rates and Prolonged Survival in Rectal Cancer Patients. Clinical Cancer Research, 2008, 14, 1073-1079.	7.0	23
167	Interpretation of Immunohistochemistry for Mismatch Repair Proteins is Only Reliable in a Specialized Setting. American Journal of Surgical Pathology, 2008, 32, 1246-1251.	3.7	112
168	Caspase-3 Activity Predicts Local Recurrence in Rectal Cancer. Clinical Cancer Research, 2007, 13, 5810-5815.	7.0	39
169	Reliability of the Roenigk Classification of Liver Damage After Methotrexate Treatment for Psoriasis. Archives of Dermatology, 2007, 143, 1515-9.	1.4	37
170	Circumferential Margin Involvement Is the Crucial Prognostic Factor after Multimodality Treatment in Patients with Locally Advanced Rectal Carcinoma. Clinical Cancer Research, 2007, 13, 6617-6623.	7.0	141
171	Cyclooxygenase 2 Expression in Rectal Cancer Is of Prognostic Significance in Patients Receiving Preoperative Radiotherapy. Clinical Cancer Research, 2007, 13, 2955-2960.	7.0	30
172	The prognostic significance of the intra-follicular tumor cell proliferative rate in follicular lymphoma. Haematologica, 2007, 92, 184-190.	3.5	57
173	Improvement of Staging by Combining Tumor and Treatment Parameters: The Value for Prognostication in Rectal Cancer. Clinical Gastroenterology and Hepatology, 2007, 5, 997-1003.	4.4	37
174	Improved reliability of lymphoma diagnostics via PCR-based clonality testing: — Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia, 2007, 21, 201-206.	7.2	279
175	Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia, 2007, 21, 207-214.	7.2	292
176	Polymerase chain reaction-based clonality testing in tissue samples with reactive lymphoproliferations: usefulness and pitfalls. A report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia, 2007, 21, 222-229.	7.2	143
177	Patients with an unexplained microsatellite instable tumour have a low risk of familial cancer. British Journal of Cancer, 2007, 96, 1605-1612.	6.4	41
178	Loss of membranous Ep-CAM in budding colorectal carcinoma cells. Modern Pathology, 2007, 20, 221-232.	5.5	109
179	Chromosomal and methylation alterations in sporadic and familial adenomatous polyposis-related duodenal carcinomas. Modern Pathology, 2007, 20, 1253-1262.	5.5	27
180	Profiling of apoptosis genes allows for clinical stratification of primary nodal diffuse large B-cell lymphomas. British Journal of Haematology, 2007, 136, 38-47.	2.5	41

#	Article	IF	Citations
181	Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan�predicts the absence of significant liver fibrosis. Liver International, 2007, 27, 639-645.	3.9	73
182	Gene expression profiling reveals two separate mechanisms regulating apoptosis in rectal carcinomas in vivo. Apoptosis: an International Journal on Programmed Cell Death, 2007, 12, 1671-1680.	4.9	3
183	Increased epithelial cell proliferation in the ileal pouch mucosa of patients with familial adenomatous polyposis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 451, 659-667.	2.8	6
184	Noninvasive monitoring of colonic carcinogenesis: feasibility of [18F]FDG-PET in the azoxymethane model. Nuclear Medicine and Biology, 2006, 33, 245-248.	0.6	20
185	Critical aneurysmal dilatation of the thoracic aorta in young adolescents with variant hyperimmunoglobulin E syndrome. Journal of Internal Medicine, 2006, 259, 615-618.	6.0	12
186	Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer. British Journal of Cancer, 2006, 94, 1035-1040.	6.4	88
187	Unfavorable pathological characteristics in familial colorectal cancer with low-level microsatellite instability. Modern Pathology, 2006, 19, 1624-1630.	5.5	10
188	Low detoxification capacity in the ileal pouch mucosa of patients with ulcerative colitis. Inflammatory Bowel Diseases, 2006, 12, 112-116.	1.9	8
189	t(3;14)(p14;q32) Results in aberrant expression of <i>FOXP1</i> in a case of diffuse large Bâ€cell lymphoma. Genes Chromosomes and Cancer, 2006, 45, 164-168.	2.8	51
190	Quantitative microsatellite analysis to delineate the commonly deleted region 1p22.3 in mantle cell lymphomas. Genes Chromosomes and Cancer, 2006, 45, 883-892.	2.8	22
191	Prognostic Value of Apoptosis in Rectal Cancer Patients of the Dutch Total Mesorectal Excision Trial: Radiotherapy Is Redundant in Intrinsically High-Apoptotic Tumors. Clinical Cancer Research, 2006, 12, 6432-6436.	7.0	42
192	Very low prevalence of germline MSH6 mutations in hereditary non-polyposis colorectal cancer suspected patients with colorectal cancer without microsatellite instability. British Journal of Cancer, 2006, 95, 1678-1682.	6.4	12
193	Integrated CGH- and Epression Array Profiling of Mantle Cell Lymphoma Blood, 2006, 108, 2252-2252.	1.4	O
194	Clinical Relevance of Occult Tumor Cells in Lymph Nodes From Gastric Cancer Patients. American Journal of Surgical Pathology, 2005, 29, 1135-1144.	3.7	29
195	Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood, 2005, 105, 301-307.	1.4	208
196	Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. Blood, 2005, 105, 2916-2923.	1.4	79
197	Novel chromosomal imbalances in mantle cell lymphoma detected by genome-wide array-based comparative genomic hybridization. Blood, 2005, 105, 1686-1693.	1.4	67
198	Expression of C-IAP1, C-IAP2 and SURVIVIN discriminates different types of lymphoid malignancies. British Journal of Haematology, 2005, 130, 852-859.	2.5	39

#	Article	IF	CITATIONS
199	Monitoring gastric lymphoma in peripheral blood by quantitative IgH allele-specific oligonucleotide real-time PCR and API2-MALT1 PCR. British Journal of Haematology, 2005, 131, 619-623.	2.5	5
200	Loss of Ep-CAM (CO17-1A) expression predicts survival in patients with gastric cancer. British Journal of Cancer, 2005, 92, 1767-1772.	6.4	75
201	Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nature Biotechnology, 2005, 23, 1407-1413.	17.5	791
202	Radiation induces different changes in expression profiles of normal rectal tissue compared with rectal carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2005, 446, 127-135.	2.8	17
203	Cost effectiveness of a new strategy to identify HNPCC patients. Gut, 2005, 54, 97-102.	12.1	78
204	Intratumoral Recombinant Human Interleukin-12 Administration in Head and Neck Squamous Cell Carcinoma Patients Modifies Locoregional Lymph Node Architecture and Induces Natural Killer Cell Infiltration in the Primary Tumor. Clinical Cancer Research, 2005, 11, 1899-1909.	7.0	80
205	FDG-PET in the detection of early pancreatic cancer in a BOP hamster model. Nuclear Medicine and Biology, 2005, 32, 445-450.	0.6	8
206	Neutrophil Defensins Enhance Lung Epithelial Wound Closure and Mucin Gene Expression (i) In Vitro (i). American Journal of Respiratory Cell and Molecular Biology, 2004, 30, 193-201.	2.9	148
207	[18F]Fluoro-2-deoxy-d-glucose Positron Emission Tomography Detects Gastric Carcinoma in an Early Stage in an Asymptomatic E-Cadherin Mutation Carrier. Clinical Cancer Research, 2004, 10, 6456-6459.	7.0	40
208	Toll-Like Receptor 2 Suppresses Immunity against <i>Candida albicans</i> through Induction of IL-10 and Regulatory T Cells. Journal of Immunology, 2004, 172, 3712-3718.	0.8	565
209	Current clinical selection strategies for identification of hereditary non-polyposis colorectal cancer families are inadequate: a meta-analysis. Clinical Genetics, 2004, 65, 308-316.	2.0	62
210	Human neutrophil defensins and secretory leukocyte proteinase inhibitor in squamous metaplastic epithelium of bronchial airways. Inflammation Research, 2004, 53, 230-238.	4.0	24
211	Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. European Journal of Surgical Oncology, 2004, 30, 643-649.	1.0	169
212	More Differences Between HNPCC-related and Sporadic Carcinomas From the Endometrium as Compared to the Colon. American Journal of Surgical Pathology, 2004, 28, 706-711.	3.7	62
213	Differential role of IL-18 and IL-12 in the host defense against disseminatedCandida albicans infection. European Journal of Immunology, 2003, 33, 3409-3417.	2.9	49
214	Very low incidence of microsatellite instability in rectal cancers from families at risk for HNPCC. Clinical Genetics, 2003, 63, 64-70.	2.0	20
215	Azathioprine and prednisone combination therapy in refractory coeliac disease. Alimentary Pharmacology and Therapeutics, 2003, 18, 487-494.	3.7	168
216	Mutual exclusion of $t(11;18)(q21;q21)$ and numerical chromosomal aberrations in the development of different types of primary gastric lymphomas. British Journal of Haematology, 2003, 123, 590-599.	2.5	23

#	Article	IF	CITATIONS
217	Proliferation and inflammation in bronchial epithelium after allergen in atopic asthmatics. Clinical and Experimental Allergy, 2003, 33, 905-911.	2.9	34
218	EBV-related lymphoproliferative disorders in immunocompetent patients. Leukemia, 2003, 17, 2537-2538.	7.2	4
219	Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia, 2003, 17, 2257-2317.	7.2	2,788
220	The Epithelial Cell Adhesion Molecule (Ep-CAM) as a Morphoregulatory Molecule Is a Tool in Surgical Pathology. American Journal of Pathology, 2003, 163, 2139-2148.	3.8	181
221	Treatment of Intra-Abdominal Abscesses Caused by Candida albicans with Antifungal Agents and Recombinant Murine Granulocyte Colony-Stimulating Factor. Antimicrobial Agents and Chemotherapy, 2003, 47, 3688-3693.	3.2	8
222	Morphological Quantification of Emphysema in Small Human Lung Specimens: Comparison of Methods and Relation with Clinical Data. Modern Pathology, 2003, 16, 1-7.	5.5	81
223	Fully Automated Assessment of Inflammatory Cell Counts and Cytokine Expression in Bronchial Tissue. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 1496-1503.	5.6	45
224	Macroscopic Evaluation of Rectal Cancer Resection Specimen: Clinical Significance of the Pathologist in Quality Control. Journal of Clinical Oncology, 2002, 20, 1729-1734.	1.6	822
225	Rhinovirus infection in nonasthmatic subjects: effects on intrapulmonary airways. European Respiratory Journal, 2002, 20, 274-279.	6.7	43
226	Enhanced Expression of Fibroblast Growth Factors and Receptor FGFR-1 during Vascular Remodeling in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory Cell and Molecular Biology, 2002, 27, 517-525.	2.9	70
227	Initial Spontaneous Remission of Posttransplantation Epstein Barr Virus-related B-Cell Lymphoproliferative Disorder of the Skin in a Renal Transplant Recipient. American Journal of Dermatopathology, 2002, 24, 414-422.	0.6	34
228	Circumferential Margin Involvement Is Still an Important Predictor of Local Recurrence in Rectal Carcinoma. American Journal of Surgical Pathology, 2002, 26, 350-357.	3.7	699
229	Germline FAS gene mutation in a case of ALPS and NLP Hodgkin lymphoma. Blood, 2002, 99, 1492-1494.	1.4	34
230	Allelic imbalance in the diagnosis of benign, atypical and malignant Spitz tumours. Journal of Pathology, 2002, 197, 170-178.	4.5	24
231	Allergen-induced impairment of bronchoprotective nitric oxide synthesis in asthma. Journal of Allergy and Clinical Immunology, 2001, 108, 198-204.	2.9	86
232	Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal Cancer. New England Journal of Medicine, 2001, 345, 638-646.	27.0	3,840
233	Tumour metastasis: is tissue an issue?. Lancet Oncology, The, 2001, 2, 109-112.	10.7	38
234	Endothelial cell chimerism after renal transplantation and vascular rejection. Lancet, The, 2001, 357, 33-37.	13.7	291

#	Article	IF	CITATIONS
235	SUCCESSFUL OUTCOME WITH A ???QUINTUPLE APPROACH??? OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER. Transplantation, 2001, 71, 47-52.	1.0	39
236	Expression of genetic markers in lymph node metastases compared with their primary tumours in head and neck cancer. Journal of Pathology, 2001, 194, 298-302.	4.5	77
237	Evaluation of the 5th edition of the TNM classification for gastric cancer: improved prognostic value. British Journal of Cancer, 2001, 84, 64-71.	6.4	47
238	Experimental rhinovirus 16 infection increases intercellular adhesion molecule-1 expression in bronchial epithelium of asthmatics regardless of inhaled steroid treatment. Clinical and Experimental Allergy, 2000, 30, 1015-1023.	2.9	67
239	Localization of Î ³ -glutamylcysteine synthetase messenger rna expression in lungs of smokers and patients with chronic obstructive pulmonary disease. Free Radical Biology and Medicine, 2000, 28, 920-925.	2.9	54
240	A case of anaplastic lymphoma kinase-positive anaplastic large cell lymphoma presenting with spontaneous splenic rupture: an extremely unusual presentation. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2000, 437, 459-464.	2.8	14
241	Pathology Data in the Central Databases of Multicenter Randomized Trials Need to Be Based on Pathology Reports and Controlled by Trained Quality Managers. Journal of Clinical Oncology, 2000, 18, 1771-1779.	1.6	49
242	Vaccination of Melanoma Patients with an Allogeneic, Genetically Modified Interleukin 2-Producing Melanoma Cell Line. Human Gene Therapy, 2000, $11,739-750$.	2.7	68
243	Gastric low-grade MALT lymphoma, high-grade MALT lymphoma and diffuse large B cell lymphoma show different frequencies of trisomy. Leukemia, 1999, 13, 799-807.	7.2	61
244	CD44 expression predicts disease outcome in localized large B cell lymphoma. Leukemia, 1999, 13, 1448-1455.	7.2	34
245	Frequent allelic imbalance but infrequent microsatellite instability in gastric lymphoma. Leukemia, 1999, 13, 1804-1811.	7.2	15
246	Total Mesorectal Excision (TME) with or without Preoperative Radiotherapy in the Treatment of Primary Rectal Cancer: Prospective Randomised Trial with Standard Operative and Histopathological Techniques. The European Journal of Surgery, 1999, 165, 410-420.	0.9	241
247	Severe hepatitis and pure red cell aplasia in adult Still's disease: good response to immunosuppressive therapy. Digestive Diseases and Sciences, 1999, 44, 1639-1642.	2.3	16
248	Superoxide dismutases in the human colorectal cancer sequence. Journal of Cancer Research and Clinical Oncology, 1999, 125, 327-335.	2.5	70
249	Classification of gastric carcinoma using the Goseki system provides prognostic information additional to TNM staging., 1999, 85, 2114-2118.		36
250	Clinical Control and Histopathologic Outcome of Asthma when Using Airway Hyperresponsiveness as an Additional Guide to Long-Term Treatment. American Journal of Respiratory and Critical Care Medicine, 1999, 159, 1043-1051.	5.6	823
251	Treatment of mesenteric desmoid tumours with the anti-oestrogen ic agent toremifene. European Journal of Gastroenterology and Hepatology, 1999, 11, 1179-1184.	1.6	41
252	Immunohistochemical detection of p53 and Bcl-2 in colorectal carcinoma: no evidence for prognostic significance. British Journal of Cancer, 1998, 77, 1842-1847.	6.4	58

#	Article	IF	CITATIONS
253	Superoxide dismutases in relation to the overall survival of colorectal cancer patients. British Journal of Cancer, 1998, 78, 1051-1057.	6.4	84
254	Lymphoma with multi-gene rearrangement on the level of immunoglobulin heavy chain, light chain, and T-cell receptor \hat{l}^2 chain. , 1998, 59, 99-100.		11
255	Myoepithelial carcinoma (malignant myoepithelioma): first report of an occurrence in the maxillary sinus. Histopathology, 1998, 32, 239-241.	2.9	28
256	Micrometastases and Survival in Stage II Colorectal Cancer. New England Journal of Medicine, 1998, 339, 223-228.	27.0	557
257	X-ray-induced lymphomagenesis in E mu-pim-1 transgenic mice: an investigation of the co-operating molecular events. Carcinogenesis, 1998, 19, 847-853.	2.8	17
258	Transforming Growth Factor \hat{l}^2 (sub) 1 (s) and Recruitment of Macrophages and Mast Cells in Airways in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 1998, 158, 1951-1957.	5.6	296
259	Enhanced expression of neutral endopeptidase (NEP) in airway epithelium in biopsies from steroidversus nonsteroid-treated patients with atopic asthma American Journal of Respiratory Cell and Molecular Biology, 1997, 16, 549-556.	2.9	42
260	Rapid Occurrence of Lymphoproliferative Disease After Pancreas-Kidney Transplantation Performed During Acute Primary Epstein-Barr Virus Infection. Clinical Infectious Diseases, 1997, 24, 339-343.	5.8	12
261	Loss of Apc and the entire chromosome 18 but absence of mutations at the Ras and Tp53 genes in intestinal tumors from Apc1638N, a mouse model for Apc-driven carcinogenesis. Carcinogenesis, 1997, 18, 321-327.	2.8	96
262	Repeatability of measures of inflammatory cell number in bronchial biopsies in atopic asthma. European Respiratory Journal, 1997, 10, 2602-2608.	6.7	31
263	Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer. British Journal of Cancer, 1997, 75, 1793-1801.	6.4	41
264	Malignant Lymphomas Stem from Different B Cell Populations. , 1997, 67, 70-84.		1
265	Visualization of mono-allelic chromosomal aberrations $3\hat{a}\in^2$ and $5\hat{a}\in^2$ of the cyclin D1 gene in mantle cell lymphoma using DNA fiber fluorescence in situ hybridization. Oncogene, 1997, 15, 1599-1603.	5.9	28
266	T cells selectively infiltrate bone marrow areas with residual haemopoiesis of patients with acquired aplastic anaemia. British Journal of Haematology, 1997, 99, 517-519.	2.5	30
267	Effective treatment of experimental lupus nephritis by combined administration of anti-CD11a and anti-CD54 antibodies. Clinical and Experimental Immunology, 1997, 108, 324-332.	2.6	36
268	Rapid verification of the identity of questionable specimens using immunohistochemistry with monoclonal antibodies directed against HLA lass I antigens. Histopathology, 1997, 31, 284-288.	2.9	12
269	Gastric lymphomas compared with lymph node lymphomas in a population-based registry differ in stage distribution and dissemination patterns but not in patient survival., 1997, 79, 390-397.		30
270	Relationship between the inflammatory infiltrate in bronchial biopsy specimens and clinical severity of asthma in patients treated with inhaled steroids Thorax, 1996, 51, 496-502.	5.6	214

#	Article	IF	Citations
271	Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study Journal of Clinical Oncology, 1996, 14, 2131-2138.	1.6	197
272	Mantle-cell lymphoma: a population-based clinical study Journal of Clinical Oncology, 1996, 14, 1269-1274.	1.6	177
273	Expression of oncoproteins and the amount of eosinophilic and lymphocytic infiltrates can be used as prognostic factors in gastric cancer. British Journal of Cancer, 1996, 74, 1783-1788.	6.4	40
274	Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. British Journal of Cancer, 1996, 74, 413-417.	6.4	268
275	Involvement of the CCND1 gene in hairy cell leukemia. Annals of Oncology, 1996, 7, 251-255.	1.2	76
276	Temporary heterotopic auxiliary liver transplantation for fulminant hepatitis B. Journal of Hepatology, 1995, 23, 109-118.	3.7	23
277	Differences in clinical behaviour and immunophenotype between primary cutaneous and primary nodal anaplastic large cell lymphoma of T-cell or null cell phenotype. Histopathology, 1993, 23, 127-135.	2.9	179
278	Prostate Marker Immunoreactivity in Salivary Gland Neoplasms. American Journal of Surgical Pathology, 1993, 17, 410-414.	3.7	143
279	The Association of c-myc Rearrangements with Specific Types of Human Non-Hodgkin's Lymphomas. Leukemia and Lymphoma, 1992, 7, 371-376.	1.3	5
280	Diffuse Aggressive B-Cell Lymphomas of the Gastrointestinal Tract: <i>An Immunophenotypic and Gene Rearrangement Analysis of 22 Cases</i> . American Journal of Clinical Pathology, 1992, 97, 170-178.	0.7	16
281	The molecular biology of B-cell lymphoma: Clinicopathologic implications. Annals of Hematology, 1991, 62, 95-102.	1.8	14
282	Discordant Morphologic Characteristics of B-Cell Lymphomas in Bone Marrow and Lymph Node Biopsies. American Journal of Clinical Pathology, 1990, 94, 59-66.	0.7	42
283	Large Pituitary Adenomas with Extension into the Nasopharynx. Annals of Otology, Rhinology and Laryngology, 1989, 98, 618-624.	1.1	28
284	The value of fine-needle aspiration biopsy in prostatic carcinoma, in comparison with core biopsy histology. World Journal of Urology, 1989, 7, 22-26.	2.2	7
285	The Distribution of Non-Hodgkinʽs Lymphoma in the Lymphoid Compartments of the Human Spleen. American Journal of Surgical Pathology, 1989, 13, 757-765.	3.7	31
286	Normal Histology of the Human Spleen. American Journal of Surgical Pathology, 1988, 12, 777-785.	3.7	66
287	Immune complexes and the pathogenesis of neutropenia in Felty's syndrome Annals of the Rheumatic Diseases, 1986, 45, 696-702.	0.9	33
288	The splenic red pulp; a histomorphometrical study in splenectomy specimens embedded in methylmethacrylate. Histopathology, 1985, 9, 401-416.	2.9	27

#	Article	IF	CITATIONS
289	The human spleen; a histological study in splenectomy specimens embedded in methylmethacrylate. Histopathology, 1985, 9, 571-585.	2.9	34